To include your compound in the COVID-19 Resource Center, submit it here.

From Actos to act two

Why blood-brain penetration data convinced Ysios to lead Minoryx's series A

The improved properties of Minoryx Therapeutics S.L.'s backup PPAR gamma agonist versus lead molecule pioglitazone were enough to convince Ysios Capital to lead the rare disease company's €19.4 million ($22.1 million) series A round.

Minoryx is developing

Read the full 379 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE